HLVX Merger Closes: $1.95/Share Plus CVRs; Director Disposes Shares
Rhea-AI Filing Summary
Julie Gerberding, a director of HilleVax, Inc. (HLVX), reported a sale of 59,224 shares of the company s common stock on 09/17/2025 in connection with a completed merger transaction. The sale occurred as part of a tender offer and merger by XOMA Royalty Corporation and its subsidiary, which paid $1.95 in cash per share plus one contingent value right (CVR) per share. At the effective time of the merger, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of the parent. Also, outstanding restricted stock units vested immediately prior to the effective time and were canceled in exchange for cash equal to $1.95 per underlying share and one CVR per underlying share.
Positive
- Merger completed with clear per-share cash consideration of $1.95 plus one CVR per share
- RSUs fully vested and settled at closing, providing immediate cash and CVR consideration to holders
Negative
- Reporting person s beneficial ownership reduced to 0 shares following the reported disposition
- Consideration includes CVRs, which are contingent and potentially introduce uncertainty about total value received
Insights
TL;DR: Transaction reflects routine equity treatment in an acquisition; insider holdings converted and RSUs settled for merger consideration.
The Form 4 discloses a director-level disposition of 59,224 common shares concurrent with a tender offer and merger. The filing indicates standard contractual treatment: cash per share of $1.95 and issuance of CVRs, with RSUs vesting and converting into cash and CVRs at the same per-share terms. From a governance perspective, this appears to be a contractual execution of change-of-control provisions rather than an opportunistic insider sale; the reporting person s post-transaction beneficial ownership is shown as zero. The filing is procedural, documenting required disclosure obligations following the merger closing.
TL;DR: Completed acquisition by XOMA Royalty Corp. paid $1.95 per share plus CVRs; RSUs accelerated and settled at closing.
The document confirms a completed tender offer and subsequent merger effective 09/17/2025, with Merger Sub merging into HilleVax and HilleVax continuing as a wholly owned subsidiary of XOMA Royalty Corporation. Consideration to shareholders consisted of $1.95 cash per share plus one contingent value right per share. The immediate vesting and cancellation of RSUs in exchange for per-share cash and CVRs is consistent with customary deal mechanics to convert outstanding equity awards into deal consideration. This is material to holders because it documents the final execution of the transaction and the settlement mechanics for equity awards.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| U | Common Stock | 59,224 | $0.00 | -- |
Footnotes (1)
- In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
